Cadrenal CEO Sells Shares, Yet Stock Rises After Social‑Media Surge
Cadrenal Therapeutics CEO sells 1,165 shares at $5.69, sparking a brief 7.7% rally driven by social‑media buzz—insider moves, funding challenges, and tecarfarin’s future weigh in.
3 minutes to read